F-1/A: Anew Health IPO Faces Going Concern Doubts Amid Profit Drop

Anew Health Limited, a Hong Kong-based pain management provider, is launching an IPO on Nasdaq but faces substantial doubt about its ability to continue as a going concern following a significant drop in net income.

Summary

• Anew Health Limited, a Cayman Islands holding company, operates pain management and health services in Hong Kong through its subsidiaries VG Zenith and Victor Zenith under the ANKH brand.
• The company offers non-surgical, non-invasive, non-pharmacological pain management and functional enhancement therapies, combining Traditional Chinese Medicine (TCM) with energy-based treatment devices.
• Anew Health also sells private-label topical use and dietary supplement products.
• The company is conducting an Initial Public Offering (IPO) of 1,800,000 Ordinary Shares, with an expected price range of US$4.00 to US$6.00 per share, and has applied to list on the Nasdaq Capital Market under the symbol AVG.
• For the fiscal year ended March 31, 2025, total revenue decreased by 1.9% to US$40.0 million from US$40.8 million in FY2024.
• Net income for FY2025 significantly decreased by 52.8% to US$5.54 million from US$11.73 million in FY2024.
• The company reported a working capital deficit of US$7,827,815 as of March 31, 2025, leading its auditor to raise substantial doubt about its ability to continue as a going concern.
• Post-IPO, AW Ocean Limited, controlled by the CEO and COO, will own 96.53% of outstanding Ordinary Shares, making Anew Health a controlled company under Nasdaq rules.
• Proceeds from the IPO are allocated to R&D (20%), establishing new service centers in Hong Kong (30%) and internationally (25%), IT system upgrades (10%), and general working capital (15%).

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including a substantial drop in net income and a working capital deficit that raises going concern doubts. While it has growth strategies and a recognized brand, the financial performance and high regulatory/political risks in Hong Kong/PRC create considerable uncertainty for investors.

Positives

• The ANKH brand is well-recognized and trusted in Hong Kong, with over 16 years of experience in pain management and functional enhancement.
• Customer satisfaction is high, with 81.7% of surveyed clients reporting satisfaction with services and 69.4% seeing a reduction in pain symptoms.
• Average annual spending per client increased by approximately 3.2% from US$6,278 in FY2024 to US$6,478 in FY2025.
• The number of clients served increased from 8,692 in FY2024 to 10,039 in FY2025.
• The company plans to expand its customer base and service center network in Hong Kong and strategically into selected global markets (Singapore, Malaysia, Japan, South Korea, Canada, and the United States).
• Commitment to enhancing R&D capabilities, including developing portable energy-based at-home treatment devices for the consumer retail market.
• The company maintains rigorous service standards and a well-established quality control and training system, resulting in a low refund rate (0.86% of contracted sales in FY2025).
• The company has a visionary senior management team with extensive industry experience and highly qualified professional advisors.

Negatives

• Net income decreased significantly by 52.8% from US$11.73 million in FY2024 to US$5.54 million in FY2025.
• Gross profit decreased by 9.1% from US$29.51 million in FY2024 to US$26.84 million in FY2025, with gross profit margin declining from 72.3% to 67.1%.
• Total revenue slightly decreased by 1.9% from US$40.8 million in FY2024 to US$40.0 million in FY2025.
• Cost of revenues increased by 16.8% due to rising personnel costs and increased headcount.
• Selling and marketing expenses increased by 16.8% to US$7.83 million in FY2025, driven by advertising and consultancy fees.
• General and administrative expenses increased by 46.8% to US$11.25 million in FY2025, largely due to increased personnel costs, including a US$1.28 million one-off discretionary bonus to directors.
• The company has a working capital deficit of US$7,827,815 as of March 31, 2025, which raises substantial doubt about its ability to continue as a going concern.
• No present plan to declare or pay any dividends on Ordinary Shares in the foreseeable future.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to working capital deficit.
• Risk of unfavorable publicity or consumer perception impacting business performance and reputation.
• Exposure to customer complaints, claims, and legal proceedings, which could result in significant costs and reputational damage.
• Potential failure to maintain the quality of equipment, treatment devices, supplies, and products, leading to liabilities and reputational harm.
• Reliance on third-party suppliers, including limited source suppliers, for products and devices, with risks of inability to produce on time or to specifications.
• Absence of long-term supply agreements with treatment device suppliers, leading to potential decreases in supply, cost increases, or quality deterioration.
• Inherent risks relating to product liability claims or product recalls, with no product liability insurance coverage.
• Challenges in hiring and retaining qualified personnel (consultants, therapists, senior management) to support growth.
• Intense competition in the pain management and health services industry, potentially leading to market share loss and reduced profitability.
• Risk that the market for products and services may not grow as expected, adversely affecting business and operating results.
• Reliance on a single geographical market (Hong Kong), making the business vulnerable to adverse economic, social, and political conditions.
• Threat of disruptive technological breakthroughs (energy-based, pharmaceutical, or other treatments) making current products/services obsolete.
• Newly opened and acquired service centers may not achieve anticipated operating results, impacting overall profitability.
• Dependence on the continued services of certain key personnel, with potential for significant business disruption if they are lost.
• Management team lacks experience in managing a U.S. public company and complying with related laws.
• Challenges in effectively maintaining, promoting, and enhancing the ANKH brand in a cost-effective manner.
• Substantial increases in rent or non-renewal of lease agreements affecting operations and financial condition.
• Cybersecurity risks, breaches, and other disruptions compromising customer personal data and treatment records, leading to liability and reputational damage.
• Potential impact of force majeure events, natural disasters, pandemic outbreaks, terrorist acts, and global political events on service center operations and customer traffic.
• Business involves significant risks and uncertainties that may not be covered by insurance.
• PRC government may exercise significant direct oversight and discretion over Hong Kong operations due to long-arm application of PRC laws and regulations, potentially changing operations or share value.
• Uncertainties regarding the requirement to obtain approvals from PRC authorities for U.S. listings and offerings, and potential for significant limitations or hindrance if required.
• Uncertainties in the interpretation and enforcement of PRC laws and regulations in Hong Kong, including data security and anti-monopoly concerns.
• Impact of the Hong Kong National Security Law and the U.S. Hong Kong Autonomy Act (HKAA) on Hong Kong subsidiaries.
• Political risks associated with conducting business in Hong Kong, including changes in political arrangements between PRC and Hong Kong.
• Changes in currency conversion rates between Hong Kong dollar and United States dollar affecting investment value.
• Corporate actions substantially controlled by AW Ocean Limited (Controlling Shareholder), potentially depriving other shareholders of a premium for their shares.
• Reliance on dividends and distributions from subsidiaries, with potential for PRC government interventions or restrictions on cash transfers out of Hong Kong.
• Difficulties in enforcing foreign civil liabilities in the Cayman Islands and Hong Kong against the company or its directors/officers.
• Limitations in protecting shareholder interests through U.S. courts due to Cayman Islands incorporation.
• Risk of Ordinary Shares being prohibited from trading on a national exchange under the Holding Foreign Companies Accountable Act (HFCAA) if the PCAOB is unable to inspect the auditor for two consecutive years.
• No prior public market for Ordinary Shares, leading to potential price volatility, difficulty in reselling, and thinly traded shares.
• Immediate and substantial dilution for new investors purchasing Ordinary Shares in the offering.
• Potential adverse effect on market price from future sales of substantial amounts of Ordinary Shares by existing shareholders.
• Decline in share price and trading volume if securities or industry analysts do not publish research or publish negative reports.
• Broad discretion in the use of net proceeds from the offering, which may not be used effectively.
• Nasdaq may apply additional and more stringent criteria for initial and continued listing due to small public offering size and large insider ownership.
• Failure to satisfy Nasdaq Capital Market listing requirements, leading to potential delisting.
• Reduced disclosure requirements as an emerging growth company may make Ordinary Shares less attractive to investors.
• Exemptions from certain U.S. provisions as a foreign private issuer may afford less protection to shareholders.
• Potential loss of foreign private issuer status, resulting in significant additional costs and expenses.
• Increased costs as a public company, particularly after ceasing to qualify as an emerging growth company.
• Reliance on price appreciation for investment return due to discretionary dividend policy.
• Potential classification as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, leading to adverse tax consequences for U.S. investors.

Future Outlook

The company intends to maintain and strengthen its market position by expanding its customer base and service center network in Hong Kong, enhancing brand awareness, and strategically expanding into selected global markets. It plans to enhance professional expertise of staff, broaden service and product offerings, and substantially enhance R&D capabilities to introduce portable energy-based at-home treatment devices. The prototype for new energy-based treatment devices is expected in early 2026, with market readiness by the end of 2026. The company does not have any present plan to declare or pay dividends in the foreseeable future, intending to retain earnings for business operation and expansion.

Management Comments

• "ANKH, stands for A New Key to Health, testifying our aspiration to be a health brand not only for alleviating physical pain but also for allowing individuals to emanate joy, health, and vitality from within and throughout."
• "We believe that our professional services, proven approach to pain management, and capability to offer a broad range of treatment services and products have enabled us to offer our clients distinguished experience at our service centers."
• "Our RDS+ approach to pain management and function enhancement therapies have been refined through over sixteen years of operation and proven by more than 400,000 services provided to our customers whom we have served."
• "The ANKH brand has become a well-recognized, trustworthy, and reliable icon in Hong Kong for the provision of quality pain management and health services."
• "We believe that we have sufficient funds to meet our operating and capital expenditure needs and obligations in the next 12 months."
• "We believe that our current cash and cash equivalents, anticipated cash flow from operations, available credit facilities, and the proceeds from this offering will be sufficient to meet our anticipated cash needs, including our cash needs for working capital and capital expenditures, for at least the next 12 months."

Industry Context

The pain management and health services industry in Hong Kong is experiencing growth, driven by an aging population and increasing awareness of chronic pain and post-COVID-19 conditions. There's a rising demand for non-pharmacological approaches due to concerns about opioid addiction and side effects of long-term medication. The market is competitive and fragmented, with a shift towards more pain-focused models and multidisciplinary management. Technological advancements and personalized care are key trends. The industry faces challenges from new entrants, limited therapist talent, and increasing operational costs, alongside potential for more stringent regulatory frameworks to prevent unfair trade practices.

Comparison to Industry Standards

• The non-pharmacological pain management market in Hong Kong is projected to grow from HKD 6,674 million in 2023 to HKD 7,882 million in 2025, reflecting a CAGR of 8.7%.
• The company is ranked No. 3 in terms of average spending per customer and No. 4 in customer experience trials among key players in the Hong Kong non-pharmacological pain management services market in 2024.
• The average spending for pain management services and products by high-income consumers in Hong Kong was HK$49,124 in 2024, a CAGR of 20.1% compared to HK$34,074 in 2022.
• Competitors like NYMG Pain Center (a subsidiary of EC Healthcare, a Hong Kong-listed company) have 25 branches, while New Hope Medical and Hong Kong Medical Pain Management Association have 2 branches each, and HK Pain Tech Institute has 5 branches, indicating a competitive landscape with larger chain centers.
• The company's services are not approved by FDA, EMA, or comparable Hong Kong regulatory authorities, and it is not subject to licensing requirements for pharmaceutical or medical devices, which differs from traditional medical clinics.

Management Changes

Corporate Governance

Legal Proceedings

• As of the date of the prospectus, the company has not been involved in any legal proceedings, investigations, or claims, nor is it aware of any pending or threatened litigation, arbitration, or other claims that would have a material adverse impact on its operations, financial position, and reputation.

Related Party Transactions

• A dividend of US$10,740,727 was declared on September 27, 2024, to AW Ocean Limited (the Controlling Shareholder) to partially offset amounts due from Mr. Ka Wai Victor, MO (CEO and Chairman).
• Mr. Ka Wai Victor, MO, CEO and Chairman, had US$1,073,723 due from him as of March 31, 2024, which was fully repaid in cash on November 7, 2024. This was an unsecured, interest-free personal loan for investment purposes.
• As of March 31, 2025, US$139,968 was due to Mr. Ka Wai Victor, MO for operational expenses paid on behalf of VG Zenith. This amount is unsecured, interest-free, and has no specific repayment terms.
• Salary compensation to Mr. Ka Wai Victor, MO was US$2,526,629 in FY2025 (vs. US$563,863 in FY2024).
• Salary compensation to Ms. Sum Lok, CHEUNG (COO and Director, spouse of Mr. Mo) was US$603,105 in FY2025 (vs. US$236,689 in FY2024).

Stakeholder Impact

• **Shareholders (Existing & New):** Existing shareholders, particularly the controlling shareholder AW Ocean Limited, will retain significant voting power (96.53% post-IPO), potentially limiting the influence of public shareholders. New investors will experience immediate and substantial dilution in book value. The going concern warning and significant profit decline pose a risk to investment value. No dividends are planned, so returns depend on share price appreciation.
• **Employees:** The company's growth strategies include maintaining and enhancing the professional expertise of frontline staff, implying continued investment in training and retention. Increased personnel costs in FY2025 suggest competitive compensation, including one-off bonuses to directors.
• **Customers:** The company aims to expand its customer base and network of service centers, develop new services and products, and enhance brand awareness, which could lead to more diverse and innovative offerings. High customer satisfaction rates (81.7%) indicate positive current impact.
• **Suppliers:** The company relies on third-party suppliers for treatment devices and products, with no long-term agreements. This could lead to supply disruptions or increased costs, potentially impacting service delivery.
• **Creditors:** The working capital deficit and going concern warning indicate potential challenges in meeting short-term obligations, which could be a concern for creditors, although the company believes IPO proceeds will provide sufficient liquidity for the next 12 months.

Next Steps

• Complete the Initial Public Offering and list Ordinary Shares on the Nasdaq Capital Market under the symbol AVG.
• Utilize IPO proceeds for research and development, establishing new service centers in Hong Kong and internationally, enhancing IT systems, and general working capital.
• Intend to establish a specialized research and development department in the first quarter of 2025.
• Release prototype of energy-based treatment devices in early 2026.
• Achieve market readiness for energy-based treatment devices by the end of 2026.
• Continue to recruit, train, and retain qualified frontline staff and senior management.
• Monitor and adapt to evolving market trends, technological advancements, and customer preferences.
• Comply with all applicable laws and regulations, including those related to data privacy and potential future PRC government oversight.

Key Dates

Recommendation

The company presents a mixed financial picture. While it demonstrates strong customer growth and increasing average spending per client, the significant decline in net income and gross profit, coupled with a persistent working capital deficit and an auditor's 'going concern' warning, signals considerable financial instability. The high concentration of ownership by the controlling shareholder and the inherent regulatory and political risks associated with operating in Hong Kong under potential PRC oversight add layers of uncertainty. The IPO proceeds are crucial for addressing liquidity and funding growth, but the underlying profitability trend is concerning. A seasoned investor would likely 'hold' or 'avoid' until there is clear evidence of sustained profitability, resolution of the going concern issue, and greater clarity on geopolitical risks, as the current risk-reward profile is unfavorable for a 'buy' recommendation.

Keywords

Pain Management, Health Services, Hong Kong, IPO, Nasdaq, Traditional Chinese Medicine, TCM, Energy-based Treatment, Wellness, Healthcare Products, SEC Filing, F-1/A, Going Concern, Corporate Governance, Risk Factors, Financial Performance, Market Expansion, Research and Development, Regulatory Risk, China Relations, Foreign Private Issuer, Controlled Company, HFCAA